CAR-GPRC5D not checked
Nanjing IASO Biotechnology Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. The CAR structure comprises a fully human single-domain antibody fragment (VHH) targeting GPRC5D, fused with intracellular co-stimulatory (4-1BB) and activation (CD3ζ) signaling domains.”In the company’s words, NCT05759793 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
- Main trialPhase 1
- “This study is a single-center, open-label, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.”In the company’s words, NCT05759793 on ClinicalTrials.gov
Other drugs for Relapsed/Refractory Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Sep 2025 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026